Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2025—Avian influenza, self-collection, and diagnostic stewardship in the microbiology laboratory are three topics of many that can be explored at the Association for Molecular Pathology meeting in Boston this November. Andrew Pekosz, PhD, heads a research laboratory at Johns Hopkins University that studies the replication and disease potential of emerging respiratory viruses.
September 2025—The largest repository of pathology slides and tissue blocks is becoming a powerful data repository with the promise to transform diagnosis and treatment through the use of artificial intelligence.
September 2025—A 68-year-old male with a history of multiple myeloma was discovered to have a 3-cm carotid body mass on PET/CT. Surgery was consulted and determined that the lesion was not amenable to surgery. Radiology favored the lesion to be a paraganglioma, so plasma metanephrine and normetanephrine were tested and were negative. With paraganglioma as the working diagnosis, germline genetic testing was performed.
September 2025—In a CAP session last year on timely topics in thyroid tumors, Zubair W. Baloch, MD, PhD, shed light on poorly differentiated and differentiated high-grade follicular-derived carcinomas. “This is something new in the WHO 5th edition of the thyroid tumor classification scheme, and I think it’s about time that we have a different category and not really split them too much,” said Dr. Baloch, an editor and author of the 5th edition of the WHO Classification of Endocrine and Neuroendocrine Tumors. Why the category is new and what to know was part of the timely topics session, for which he paired up with Nikolina Dioufa, MD, PhD, MSc, who spoke about noninvasive follicular thyroid neoplasm with papillary-like nuclear features and follicular variant of papillary thyroid carcinoma.
September 2025—Leaders of the Digital Pathology Association met online with CAP TODAY publisher Bob McGonnagle to talk about digital pathology and much that’s related: adoption, investment, and artificial intelligence tools. “Most people are playing catch-up,” Marilyn Bui, MD, PhD, past president of the DPA and a member of the association’s board of directors, said of digital pathology. Of AI and digital pathology, DPA Foundation president Michael Rivers of Roche Tissue Diagnostics said, “Over the next several years we’re going to see a transformation in pathology.”
September 2025—Enrollment is underway now for a new CAP study that will make it possible for individual and integrated laboratories to compare inpatient analyte volumes and identify ordering practice problems. “This study is the first by the CAP that will allow system laboratories to evaluate a quality metric—inpatient test utilization—across all laboratories within their system and in comparison to like system laboratories across the U.S. and beyond,” says Richard Brown, MD, former chair and now advisor to the CAP Quality Practices Committee, whose members developed the study.
September 2025—The efficacy of human epidermal growth factor receptor 2 antibody-drug conjugate therapy for treating HER2-low breast cancers necessitates more accurate and reproducible HER2 IHC scoring. The authors conducted a study to validate the performance and utility of a fully automated artificial intelligence (AI) solution for interpreting HER2 IHC in breast carcinoma. In the two-arm multireader study of 120 HER2 IHC whole slide images from four sites, four surgical pathologists assessed HER2 scoring with and without the aid of an AI solution. Both arms of the study were compared with high-confidence ground truth established by agreement of at least four of five breast pathology subspecialists according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 2018 and 2023 guidelines. The mean interobserver agreement among the ground truth pathologists across all HER2 scores was 72.4 percent (n =120).
September 2025—When someone dies suddenly and unexpectedly, a forensic autopsy is often performed to identify the manner and cause of death. However, up to 30 percent of autopsies fail to identify any underlying anatomic or toxicologic etiologies, and the autopsy classification may be sudden unexplained death. This is particularly concerning in young people, in whom the cause could be an inherited genetic condition that could also affect family members. Therefore, postmortem genetic testing, also known as a molecular autopsy, may have utility in identifying underlying inherited diseases that could contribute to death. In many cases, sudden death is due to cardiac factors, but the type of cardiac dysfunction may depend on age.
September 2025—In his previous role as a pathologist at Seattle’s Virginia Mason Medical Center, Dick Hwang, MD, PhD, was looking for a way to make his life—and his colleagues’ lives—easier. So he reached for something he hadn’t used in a while: his doctorate in computational biology. It was 2014, and Virginia Mason’s pathology group had just rolled out M*Modal Fluency Direct speech-recognition software as an optional tool for dictating diagnostic data. Dr. Hwang and many of his colleagues embraced the new software, but they soon realized that it meant they’d be spending a lot of time editing and formatting data. Entering a final diagnosis required, for example, typing “1.{tab}{caps lock},” dictating “cecum and ascending colon comma polypectomy,” then typing “:{caps lock}{return}{backspace}A.{tab}”—just as a start.
September 2025—CAP president Donald Karcher, MD, in a July 25 letter urged the chairs and ranking members of the Senate and House appropriations subcommittee on labor, health and human services, education, and related agencies to apply pressure to obligate and award already approved funding for the CDC Division of Cancer Prevention and Control. “Even though Congress approved FY 2025 funding in March, the CDC has not issued notice of awards to provide funding to state and local health departments for the remaining FY 2025 funds,” he said. “State and local health departments are challenged to continue their work without knowing if they will be reimbursed. State health departments and grantees are on the verge of shutting down programs and furloughing staff.”
